ArticleFuture medicinal chemistry2021

Engineering 'Enzymelink' for screening lead compounds to inhibit mPGES-1 while maintaining prostacyclin synthase activity.

Diana T Ruan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.